Clinical and morphological features of the myometrium in patients with placental adherent and invasive pathology
- Authors: Zazerskaya I.E.1,2, Ponikarova N.Y.1, Tolibova G.K.2, Tral T.G.2, Roshchina T.Y.1, Shelepova E.S.1, Yukova A.D.1
-
Affiliations:
- Almazov National Medical Research Centre
- The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
- Issue: Vol 73, No 4 (2024)
- Pages: 19-30
- Section: Original study articles
- URL: https://bakhtiniada.ru/jowd/article/view/268537
- DOI: https://doi.org/10.17816/JOWD632710
- ID: 268537
Cite item
Abstract
BACKGROUND: The fast increase in the frequency of placental adherent and invasive pathology worldwide accounts for the growing interest in studying the pathogenesis of placenta accreta. According to the literature, the clinical and morphological features of the myometrium from the placental attachment area in placental adherent and invasive pathology are described in single articles. Study of morphological features using proteolytic markers in the myometrium from the placenta accreta area could help in understanding the pathogenesis of placental adherent and invasive pathology. For the first time in this study, the clinical and morphological features of the myometrium from the placental attachment area in patients with uterine scar and placental adherent and invasive pathology are compared with the myometrium of women with uterine scar without placenta accreta and intact myometrium.
AIM: The aim of this study was to evaluate the expression of matrix metalloproteinase 2 and tissue inhibitors of matrix metalloproteinases 1 and 2 in myometrial biopsies in placental adherent and invasive pathology.
MATERIALS AND METHODS: This study included 15 myometrial biopsies from the placental site, which were divided into three groups according to the clinical diagnosis of the patients: group 1 (main group), with a uterine scar after cesarean section and placental adherent and invasive pathology (n = 5); group 2 (comparison group), with a uterine scar after cesarean section (n = 5); group 3 (control group), with a normal pregnancy without a uterine scar (n = 5). Histological examination was carried out using the standard procedure. Immunohistochemical study was performed using antibodies to matrix metalloproteinase 2 and tissue inhibitors of matrix metalloproteinases 1 and 2 (Abcam, USA). Morphometry was carried out using the VideoTesT-Morphology 5.2 program (Videotest Ltd., Russia). The statistical analysis was performed using the IBM SPSS Statistics 26.0 software.
RESULTS: In the biopsies of the main group, we verified terminal chorionic villi with hypervascularization and uneven plethora of the vascular bed among hypertrophied muscle fibers, a basal plate with lumen ectasia of unevenly full-blooded vessels, and the absence of a decidual membrane, in contrast to groups 2 and 3. The matrix metalloproteinase 2 expression area in the main group was higher than in the comparison and control groups (p = 0.008; p1–2 = 0.049*, p1–3 = 0.011), the matrix metalloproteinase 2 optical density not differing between the groups (p = 0.122). The tissue inhibitors of matrix metalloproteinases 1 expression area was higher in the comparison group compared to the main group (p = 0.035; p2–3 = 0.032), and the tissue inhibitors of matrix metalloproteinases 1 and 2 optical density was higher in the comparison group compared to control (p = 0.008; p2–3 = 0.005).
CONCLUSIONS: In myometrial biopsies of patients with a uterine scar and placental adherent and invasive pathology, we verified pathology of the basal plate of the placenta, increased matrix metalloproteinase 2 expression and decreased tissue inhibitors of matrix metalloproteinases 1 expression, which may indicate the peculiarities of the inflammatory response in the myometrium in placental adherent and invasive pathology.
Full Text
##article.viewOnOriginalSite##About the authors
Irina E. Zazerskaya
Almazov National Medical Research Centre; The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: zazera@mail.ru
ORCID iD: 0000-0003-4431-3917
SPIN-code: 5683-6741
MD, Dr. Sci. (Medicine), Professor
Russian Federation, Saint Petersburg; Saint PetersburgNataliya Yu. Ponikarova
Almazov National Medical Research Centre
Author for correspondence.
Email: natalyponi@gmail.com
ORCID iD: 0000-0002-7230-3057
SPIN-code: 8527-5644
MD, postgraduate student
Russian Federation, Saint PetersburgGulrukhsor Kh. Tolibova
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: gulyatolibova@mail.ru
ORCID iD: 0000-0002-6216-6220
SPIN-code: 7544-4825
MD, Dr. Sci. (Medicine)
Russian Federation, Saint PetersburgTatiana G. Tral
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Email: ttg.tral@yandex.ru
ORCID iD: 0000-0001-8948-4811
SPIN-code: 1244-9631
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgTatiana Yu. Roshchina
Almazov National Medical Research Centre
Email: tanya.roshchina.69@mail.ru
ORCID iD: 0000-0002-2169-1782
MD
Russian Federation, Saint PetersburgEkaterina S. Shelepova
Almazov National Medical Research Centre
Email: shelepova_es@almazovcentre.ru
ORCID iD: 0000-0002-3233-8239
SPIN-code: 9474-1351
MD, Cand. Sci. (Medicine)
Russian Federation, Saint PetersburgAlina D. Yukova
Almazov National Medical Research Centre
Email: lina.salimova.97@bk.ru
ORCID iD: 0009-0005-2534-2845
Russian Federation, Saint Petersburg
References
- Collins SL, Alemdar B, Van Beekhuizen HJ, et al. Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019;220(6):511–526. doi: 10.1016/j.ajog.2019.02.054
- Collins SL, Chantraine F, Morgan TK, et al. Abnormally adherent and invasive placenta: a spectrum disorder in need of a name. Ultrasound Obstet Gynecol. 2018;51(2):165–166. doi: 10.1002/uog.18982
- Pegu B, Thiagaraju C, Nayak D, et al. Placenta accreta spectrum – a catastrophic situation in obstetrics. Obstet Gynecol Sci. 2021;64(3):239–247. doi: 10.5468/ogs.20345
- Illsley NP, DaSilva-Arnold SC, Zamudio S, et al. Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta). Placenta. 2020;102:61–66. doi: 10.1016/j.placenta.2020.01.004
- American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus N 7: placenta accreta spectrum. Obstet Gynecol. 2018;132(6):e259–e275. doi: 10.1097/AOG.0000000000002983
- Tinari S, Buca D, Cali G, et al. Risk factors, histopathology and diagnostic accuracy in posterior placenta accreta spectrum disorders: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2021;57(6):903–909. doi: 10.1002/uog.22183
- Long Y, Jiang Y, Zeng J, et al. The expression and biological function of chemokine CXCL12 and receptor CXCR4/CXCR7 in placenta accreta spectrum disorders. J Cell Mol Med. 2020;24(5):3167–3182. doi: 10.1111/jcmm.14990
- Demir-Weusten AY, Seval Y, Kaufmann P, et al. Matrix metalloproteinases-2, -3 and -9 in human term placenta. Acta Histochem. 2007;109(5):403–412. doi: 10.1016/j.acthis.2007.04.001
- Jauniaux E, Alfirevic Z, Bhide AG, et al. Placenta praevia and placenta accreta: diagnosis and management: green-top guideline N 27a. BJOG Int J Obstet Gynaecol. 2019;126(1): e1–e48. doi: 10.1111/1471-0528.15306
- Shmakov RG, Kurtser MA, Barinov SV, et al. Pathological attachment of the placenta (placenta previa and accreta). Draft clinical recommendations. [cited 2024 May 25]. Moscow; 2023. EDN: UPVLFD Available from: https://roag-portal.ru/recommendations_obstetrics (In Russ.)
- Zazerskaya IE, editor. Clinical protocols for the management of patients in the specialty “Obstetrics and gynecology”. In 2 Vol. Part I. 3rd ed. Saint Petersburg: Eco-Vector; 2023. EDN: YFLBCL
- Semenova ES, Mashchenko IA, Trufanov GE, et al. Magnetic resonance imaging during pregnancy: current safety issues. REJR. 2020;10(1):216–230. (In Russ.). EDN: KTBZTW doi: 10.21569/2222-7415-2020-10-1-216-230
- Vyshedkevich ED, Semenova ES, Mashchenko IA, et al. Methodological aspects of the development of topographic-anatomical segmentation of the uterus in the second and third trimesters of pregnancy on MRI. Translational Medicine. 2021;8(1):51–59. (In Russ.) EDN: MVZBBV doi: 10.18705/2311-4495-2021-8-1-51-59
- AbdelFattah S, Morsy M, Ahmed AM, et al. Microcellular approach for the pathogenesis of placenta accreta spectrum inflammatory versus apoptotic pathways; a thorough look on Treg, dNK and VEGF. Pathol Res Pract. 2024;254:155153. doi: 10.1016/j.prp.2024.155153
- Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017; 217:27–36. doi: 10.1016/j.ajog.2017.02.050
- Hecht JL, Baergen R, Ernst LM, et al. Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: recommendations from an expert panel. Mod Pathol. 2020;12(33):2382–2396. doi: 10.1038/s41379-020-0569-1
- Suardi D, Toriq H, Tuasikal RR, et al. Comparison of extravillous intermediate trophoblast invasion depth and distribution pattern between placenta accreta and non-accreta. Med Sci Monit. 2023;29(6):e939125. doi: 10.12659/MSM.939125
- Cramer SF, Heller DS. Placenta accreta and placenta increta: an approach to pathogenesis based on the trophoblastic differentiation pathway. Pediatr Dev Pathol. 2016;19(4):320–333. doi: 10.2350/15-05-1641-OA.1
- DaSilva-Arnold SC, Zamudio S, Al-Khan A, et al. Human trophoblast epithelial-mesenchymal transition in abnormally invasive placenta. Biol Reprod. 2018;99(2):409–421. doi: 10.1093/biolre/ioy042
- Wang R, Liu W, Zhao J, et al. Overexpressed LAMC2 promotes trophoblast over-invasion through the PI3K/Akt/MMP2/9 pathway in placenta accreta spectrum. J Obstet Gynaecol Res. 2023;49(2):548–559. doi: 10.1111/jog.15493
- Bartels HC, Postle JD, Downey P, et al. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis Markers. 2018;2018:1–11. doi: 10.1155/2018/1507674
- Jing M, Chen X, Qiu H, et al. Insights into the immunomodulatory regulation of matrix metalloproteinase at the maternal-fetal interface during early pregnancy and pregnancy-related diseases. Front Immunol. 2022;13:1067661. doi: 10.3389/fimmu.2022.1067661
- Soyama H, Miyamoto M, Ishibashi H, et al. Placenta previa may acquire invasive nature by factors associated with epithelial-mesenchymal transition and matrix metalloproteinases. J Obstet Gynaecol Res. 2020;46(2):526–533. doi: 10.1111/jog.14485
- Lukashevich AA, Aksenenko VA, Milovanov AP, et al. Placenta accreta forecasting using serum marker values. Doctor.Ru. 2020;19(1):6–11. (In Russ.) doi: 10.31550/1727-2378-2020-19-1-6-11
Supplementary files
